Enyx Therapeutics LLC

Enyx Therapeutics LLC is a partnership or limited liability partnership registered with SAM.gov since February 24, 2022. As an early-stage biotechnology company, Enyx Therapeutics focuses on developing innovative gene therapy approaches to address unmet medical needs. The company has secured multiple federal grant awards from the National Institutes of Health to support its research and development efforts in areas such as enhancing fat graft survival, treating hereditary angioedema, and addressing eosinophilic esophagitis.

Through its federal grant awards, Enyx Therapeutics is advancing several promising gene therapy projects. The company received a $295,901 grant from the National Human Genome Research Institute to develop a novel gene therapy approach using an adenovirus vector (ENX02) to enhance the survival of autologous fat transplants. This project aims to improve outcomes for patients undergoing reconstructive and aesthetic procedures. Additionally, Enyx secured a $275,737 grant from the National Institute of Allergy and Infectious Diseases to assess the safety of ENX05, an adeno-associated virus (AAV)-mediated gene therapy for hereditary angioedema, in non-human primates. The company also obtained a $600,000 grant to develop LXI02, another AAV-based gene therapy designed to express an anti-Siglec-8 monoclonal antibody for the treatment of eosinophilic esophagitis. These projects demonstrate Enyx Therapeutics' focus on leveraging gene therapy technologies to address a diverse range of medical conditions, with funding support primarily coming from various institutes within the National Institutes of Health.